| Popis: |
Aim: Although lung cancer and COPD have similar etiologic factors, the relationship between these diseases has not been investigated. The aim of this study was to investigate TGF-β polymorphisms whether it is effective in the development of lung cancer in COPD patients or not. Material and Method: Seventy-eight patients were divided into three groups; group 1: 28 patients with COPD and lung cancer, group 2: 30 patients with COPD and group 3: 20 healthy people as a control group. We investigated 10 TGF-β polymorphisms in these patients over the age of 40 who were not relatives. Demographic data and polymorphism results of the patients were evaluated by an online access program provided by the Insttitute of Human Genetics using the Statistical Package for the Social Sciences v.22.0 program and the DeFinetti program provided by an online resource using the Armitage trend test. Results: Wild alleles were especially in dominant in healthy individuals, rs11466345 T>C, rs1800470-2 G>C, rs1800471-1 C>G, rs1800471-2 C>T, rs1877474-2 T>G polymorphisms. They were not associated with lung cancer and COPD development. However, two polymorphisms, rs1800470-1 G>A and rs1800469 A>G, had a protective effect against lung cancer development, especially rs1800470-1 G>A polymorphism was found more protective in former smokers than smokers. Conclusions: rs1800470-1 G>A and rs1800469 A>G were protective against lung cancer development. Furthermore, rs1800470-1 G>A polymorphism was found more protective in former smokers than smokers. These polymorphisms may evaluate the risk of COPD and lung cancer development in healthy people, lung cancer development in patients with COPD and to determine the frequency of follow-up. |
